PHOENIX — Arizona lawmakers are moving forward with a bill that would fund clinical trials of a psychedelic drug that could help veterans.
House Bill 2871 would appropriate $5 million to fund clinical trials that investigate the medical uses of ibogaine, a substance that could potentially treat traumatic brain injuries and other conditions, such as Parkinson’s Disease and Alzheimer’s.
This could help the drug ...
In addition to iboga and ibogaine, Forynja and Björnsdóttir say they are also interested in the implementation of MDMA-assisted therapy for patients …
An update from Universal Ibogaine Inc ( (TSE:IBO) ) is now available.
Universal Ibogaine Inc. has announced a bi-weekly update regarding its delay in filing annual audited financial statements and related documents, which led to a management cease trade order (MCTO) from the Alberta Securities Commission. The company plans to complete the required filings by ...
Ibogaine by David Dardashti, a leading voice in the exploration of ibogaine’s therapeutic potential, is closely analyzing a new study published in EMBO Reports that sheds light on the intricate genetic mechanisms underlying neurological disorders, including Parkinson’s disease. This research, spearheaded by Associate Professor Masahito Yoshihara and colleagues, provides compelling evidence that could significantly impact the ...
In a study that was featured in Nature Chemistry, researchers at UC Davis have shown that it is possible to manufacture the psychedelic ibogaine without having to harvest tons of the plant in which this substance occurs naturally.
Many companies like Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) are striving to take different psychedelic compounds through the…